Terms: = Lymphoma AND DDIT3, CHOP, 1649, ENSG00000175197, _C/EBP zeta_, MGC4154, GADD153, CHOP10, P35638 AND Clinical Outcome
140 results:
1. clinical significance of plasma PD-L1
Xu P; Liu J; Chen H; Shang L; Wang F; Zhu Y; Guo Y; Li F; Yan F; Xie X; Li L; Gu W; Lin Y
Ann Hematol; 2023 Sep; 102(9):2435-2444. PubMed ID: 37162517
[TBL] [Abstract] [Full Text] [Related]
2. Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome.
Viswanathan A; Kundal K; Sengupta A; Kumar A; Kumar KV; Holmes AB; Kumar R
Brief Funct Genomics; 2023 Jan; 22(1):42-48. PubMed ID: 36412115
[TBL] [Abstract] [Full Text] [Related]
3. Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-chop therapy.
Tyryshkin K; Moore A; Good D; Popov J; Crocker S; Rauh MJ; Baetz T; LeBrun DP
Leuk Lymphoma; 2023 Jan; 64(1):119-129. PubMed ID: 36336953
[TBL] [Abstract] [Full Text] [Related]
4. KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
Kaddu-Mulindwa D; Altmann B; Robrecht S; Ziepert M; Regitz E; Tausch E; Held G; Poeschel V; Lesan V; Bittenbring JT; Thurner L; Pfreundschuh M; Christofyllakis K; Truemper L; Loeffler M; Schmitz N; Hoth M; Hallek M; Fischer K; Stilgenbauer S; Bewarder M; Rixecker TM
Lancet Haematol; 2022 Feb; 9(2):e133-e142. PubMed ID: 35114151
[TBL] [Abstract] [Full Text] [Related]
5. clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's lymphoma and Role of
Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
[TBL] [Abstract] [Full Text] [Related]
6. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model.
Xie W; Liu MK; Jiang XF; Gao XD; Li B; Wang L; Zhao WL
Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799
[TBL] [Abstract] [Full Text] [Related]
7. Activity of ibrutinib plus R-chop in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
[TBL] [Abstract] [Full Text] [Related]
9. clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-chop in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
Zhang MC; Fang Y; Wang L; Cheng S; Fu D; He Y; Zhao Y; Wang CF; Jiang XF; Song Q; Xu PP; Zhao WL
Clin Epigenetics; 2020 Oct; 12(1):160. PubMed ID: 33097085
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
[TBL] [Abstract] [Full Text] [Related]
11. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
Witte HM; Merz H; Biersack H; Bernard V; Riecke A; Gebauer J; Lehnert H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2020 Apr; 189(2):257-268. PubMed ID: 31958882
[TBL] [Abstract] [Full Text] [Related]
12. A case report of primary prostate intravascular large B cell lymphoma presenting as prostatic hyperplasia.
Zhu F; Pan H; Xiao Y; Li Q; Liu T; Liu X; Wu G; Li J; Zhang L
Medicine (Baltimore); 2019 Dec; 98(50):e18384. PubMed ID: 31852153
[TBL] [Abstract] [Full Text] [Related]
13. Ukraine Data on Prognostic Factors and Treatment outcomes in Patients with Peripheral T-Cell lymphomas.
Skrypets T; Novosad O; Pastushenko Y; Gorbach O; Kriachok I
Klin Onkol; 2019; 32(6):436-444. PubMed ID: 31842562
[TBL] [Abstract] [Full Text] [Related]
14. Aggressive B-cell lymphoma: chasing the target.
Walewski J
J Investig Med; 2020 Feb; 68(2):331-334. PubMed ID: 31672721
[TBL] [Abstract] [Full Text] [Related]
15. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
[TBL] [Abstract] [Full Text] [Related]
16. A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma-diffuse large B-cell lymphoma (DOBL study): Study protocol and design.
Goda JS; Lewis SC; Laskar S; Kannan S; Khanna N; Jain H; Bagal B; Epari S
Cancer Rep (Hoboken); 2019 Apr; 2(2):e1161. PubMed ID: 32935480
[TBL] [Abstract] [Full Text] [Related]
17. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Jamois C; Gibiansky E; Gibiansky L; Buchheit V; Sahin D; Cartron G; Marcus R; Hiddemann W; Seymour JF; Strefford JC; Hargreaves CE; Meneses-Lorente G; Frey N; Fingerle-Rowson G
Br J Clin Pharmacol; 2019 Jul; 85(7):1495-1506. PubMed ID: 30866056
[TBL] [Abstract] [Full Text] [Related]
18. [Survival Analysis of 148 Patients with Primary Diffuse Large B Cell lymphoma].
Xu YR; Liu L; Ren XH; Liu PP; Zhang H; Zheng L; Zhang SS; Zhou LQ; Guo ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):61-66. PubMed ID: 30738448
[TBL] [Abstract] [Full Text] [Related]
19. Primary Cardioprotection Reduces Mortality in lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-chop Regimen.
Długosz-Danecka M; Gruszka AM; Szmit S; Olszanecka A; Ogórka T; Sobociński M; Jaroszyński A; Krawczyk K; Skotnicki AB; Jurczak W
Chemotherapy; 2018; 63(4):238-245. PubMed ID: 30372698
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract] [Full Text] [Related]
[Next]
